Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Research points towards new blindness prevention methods in diabetic eye disease

By combining data on optometry patient's eyes with advanced computational methods, Indiana … Read More

Detecting diabetic eye disease with machine learning

Diabetic retinopathy — an eye condition that affects people with diabetes — is the fastest growing … Read More

Cause of inflammation in diabetes identified

Inflammation is one of the main reasons why people with diabetes experience heart attacks, strokes, … Read More

More News

Wednesday, January 18th, 2017 at 10:48am
Allergan Rebounding With Strong Product Pipeline, Smart Acquisitions - TheStreet https://t.co/rIH4UljWFN
Tuesday, January 17th, 2017 at 6:21pm
Biotech firms form patent alliance over interference proceeding against CRISPR patent application https://t.co/EC18AhtEhd
Ophthalmic Contract Research